Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: The association with disease activity and survival

Haematologica

Volumn 91, Issue 2, 2006, Pages 200-206

  Van De Broek, Isabelle ^a   Leleu, Xavier ^b   Schots, Rik ^a   Facon, Thiery ^b   Vanderkerken, Karin ^a   Van Camp, Ben ^c   Van Riet, Ivan ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c NONE

Author keywords

Chemokine receptor expression; Homing; Multiple myeloma; Survival

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR4; HEMOGLOBIN;

ADULT; AGED; ARTICLE; BONE MARROW; CELL SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; FISHER EXACT TEST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR4; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 33644529120     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997;336: 1657-64.
2. Hallek, M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21.
3. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000;355:248-50.
4. Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001; 28:607-12.
5. Witzig T, Dhodapkar M, Kyle R, Greipp P. Quantification of circulating peripteral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer 1993;72:108-13.
6. Witzig T, Gertz MA, Lust JA, Kyle RA, O'Fallon W, Greipp P. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 1996;88:1780-7.
7. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-14.
8. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60-6.
9. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-8.
10. Nelson PJ, Krensky AM. Chemokines, lymphocytes and viruses: what goes around, comes around. Curr Opin Immunol 1998;10:265-70.
11. Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. Adv Immunol 1999;72:209-53.
12. Van de Broek I, Asosingh K, Vanderkerken K, Straetmans N, Van Camp B. Van Riet I. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer 2003;88:855-62.
13. Moller C, Stromberg T, Juremalm M, Nilsson K, Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia 2003;17:203-10.
14. Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 2003;170:1136-40.
15. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842-54.
16. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121:749-57.
17. Pellat-Deceunynck C. Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge-Morineau N, et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 1994;84:2597-603.
18. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ; Southwest Oncology Group. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 2003;122:441-50.
19. Durie BG, KylIe RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Scientific Advisors of the International Myeloma Foundation. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003;4:379-98.
20. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23: 3412-20.
21. Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol 1997;97:46-55.
22. Kumar S, Rajkumar SV, Greipp PR, Witzig TE. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments. Am J Hematol 2004;77:7-11.
23. Gazitt Y, Akay C. Mobilization of myeloma cells involves SDF-1/CXCR4 signaling and downregulation of VLA-4. Stem Cells 2004;22:65-73.
24. Spano JP, Andre F, Morat L, Sabatier L, Besse B, Combadiere C, et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol 2004;15:613-7.
25. Benovic JL, Marchese A. A new key in breast cancer metastasis. Cancer Cell 2004;6:429-30.
26. Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004; 104:550-7.
27. Crazzolara R, Kreczy A, Mann G, Heitger A, Eibl G, Fink FM, et al. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol 2001;115:545-53.
28. Ghobrial IM, Bone ND, Stenson MJ, Novak A, Hedin KE, Kay NE, et al. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Mayo Clin Proc 2004;79:318-25.
29. Kallinich T, Muche JM, Qin S, Sterry W, Audring H, Kroczek RA. Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. J Invest Dermatol 2003;121:1045-5.
30. Sato N, Matsubayashi H, Fukushima N, Goggins M. The chemokine receptor CXCR4 is regulated by DNA methylation in pancreatic cancer. Cancer Biol Ther 2005;4:70-6.
31. Chim CS, Wong SY, Kwong YL. Aberrant gene promoter methylation in acute promyelocytic leukaemia: profile and prognostic significance. Br J Haematol 2003;122:571-8.
32. Galm O, Wilop S, Reichelt J, Jost E, Gehbauer G, Herman JG, Osieka R. DNA methylation changes in multiple myeloma. Leukemia. 2004;18:1687-92.